ArticleThe American journal of pathology1998
Novel short-fragment PCR assay for highly sensitive broad-spectrum detection of anogenital human papillomaviruses.
Article in The American journal of pathology, 1998. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 176 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
176 citing papers in PubMed, 514 citations in OpenAlex.
- Design and initial findings of a natural history study of anal HPV and associated lesions among young adult women in Costa Rica.International journal of cancer · 2025Trial
- Comparing one dose of HPV vaccine in girls aged 9-14 years in Tanzania (DoRIS) with one dose of HPV vaccine in historical cohorts: an immunobridging analysis of a randomised controlled trial.The Lancet. Global health · 2022Trial
- Durability of Cross-Protection by Different Schedules of the Bivalent HPV Vaccine: The CVT Trial.Journal of the National Cancer Institute · 2020Trial
- Trial
- Durability of Protection Afforded by Fewer Doses of the HPV16/18 Vaccine: The CVT Trial.Journal of the National Cancer Institute · 2018Trial
- Evaluation of Type Replacement Following HPV16/18 Vaccination: Pooled Analysis of Two Randomized Trials.Journal of the National Cancer Institute · 2017Trial
- Multisite HPV16/18 Vaccine Efficacy Against Cervical, Anal, and Oral HPV Infection.Journal of the National Cancer Institute · 2016Trial
- Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA Trials.The Lancet. Oncology · 2015Trial
- Post hoc analysis of the PATRICIA randomized trial of the efficacy of human papillomavirus type 16 (HPV-16)/HPV-18 AS04-adjuvanted vaccine against incident and persistent infection with nonvaccine oncogenic HPV types using an alternative multiplex type-specific PCR assay for HPV DNA.Clinical and vaccine immunology : CVI · 2015Trial
- Reduced prevalence of vulvar HPV16/18 infection among women who received the HPV16/18 bivalent vaccine: a nested analysis within the Costa Rica Vaccine Trial.The Journal of infectious diseases · 2014Trial
- Effect of different human papillomavirus serological and DNA criteria on vaccine efficacy estimates.American journal of epidemiology · 2014Trial
- Efficacy of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical intraepithelial neoplasia and cervical infection in young Japanese women.Human vaccines & immunotherapeutics · 2014Trial
- Trial
- Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine.Journal of the National Cancer Institute · 2011Trial
- Prevention of persistent human papillomavirus infection by an HPV16/18 vaccine: a community-based randomized clinical trial in Guanacaste, Costa Rica.Cancer discovery · 2011Trial
- Efficacy of a bivalent HPV 16/18 vaccine against anal HPV 16/18 infection among young women: a nested analysis within the Costa Rica Vaccine Trial.The Lancet. Oncology · 2011Trial
- Trial
- Highly effective detection of human papillomavirus 16 and 18 DNA by a testing algorithm combining broad-spectrum and type-specific PCR.Journal of clinical microbiology · 2006Trial
- Wastewater-Based Surveillance of Human Papillomavirus Genotype Diversity.JAMA network open · 2026Article
- Comparative performance of L1- and E6/E7-targeted HPV genotyping assays based on a unified MeltArray platform.Microbiology spectrum · 2026Article
116 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A novel set of polymerase chain reaction (PCR) primers, designated SPF1 and SPF2 and located in the L1 region, was developed for universal detection of human papillomavirus (HPV). A short PCR fragment (SPF) of only 65 pb was synthesized. SPF amplimers were detected in a microtiter-based hybridization system, using a mixture of oligonucleotide probes. The SPF system allowed detection of at least 43 different HPV genotypes. The clinical performance of the novel SPF system was assessed in three different patient groups. 1) Analysis of 534 cervical scrapes, obtained from treated patients, showed that the detection rate in 447 (83.7%) scrapes with normal cytology was significantly higher using the SPF system as compared with the universal primer set GP5+/6+ (P < 0.001). 2) The SPF assay detected HPV DNA in 299 (98.4%) of 304 scrapes with cytological dyskaryosis. 3) The SPF system detected HPV DNA in 100% of 184 formalin-fixed, paraffin-embedded cervical carcinoma specimens. In conclusion, the novel SPF system permitted universal and highly sensitive detection of HPV DNA in diverse clinical materials and may improve the molecular diagnosis and epidemiology of this important virus.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.